




- (51) **International Patent Classification:**
C12N 15/00 (2006.01) C12N 15/85 (2006.01)
- (21) **International Application Number:**
PCT/US2015/022660
- (22) **International Filing Date:**
26 March 2015 (26.03.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/970,794 26 March 2014 (26.03.2014) US
- (71) **Applicant:** UNIVERSITY OF MARYLAND, COLLEGE PARK [US/US]; Office of Technology Commercialization, 2130 Mitchell Building, College Park, Maryland 20742 (US).
- (72) **Inventors:** TELUGU, Bhanu Prakash V.L.; University of Maryland, College Park, Office of Technology Commercialization, 2130 Mitchell Building, College Park, Maryland 20742 (US). PARK, Ki-Eun; University of Maryland, College Park, Office of Technology Commercialization, 2130 Mitchell Building, College Park, Maryland 20742 (US).
- (74) **Agents:** NEBEL, Heidi S. et al.; McKee, Voorhees & Sease, P.L.C., 801 Grand Avenue, Suite 3200, Des Moines, Iowa 50309-2721 (US).

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** TARGETED GENOME EDITING IN ZYGOTES OF DOMESTIC LARGE ANIMALS



Pig zygote

Mouse zygote

FIG. 1

(57) **Abstract:** A method is provided of targeted genome editing of an animal using site specific homologous integration. A composition comprising a single stranded oligonucleotide or double stranded nucleic acid molecule comprising a nucleic acid molecule of interest and sequences flanking a target locus cleavage site is injected into the zygote of an animal along with a nuclease and a guide nucleic acid molecule that targets the nuclease to a target locus. The composition is injected into the zygote after fertilization and prior to formation of a nucleus. The nucleic acid molecule of interest is recombined into the genome with high efficiency. The process allows for integration of nucleic acid molecules into the genome of animals in which the pronuclei cannot be visually observed during injection.



**TITLE: TARGETED GENOME EDITING IN ZYGOTES OF DOMESTIC
LARGE ANIMALS**

5 **CROSS-REFERENCE TO RELATED APPLICATIONS**

This application claims priority under 35 U.S.C. § 119 to provisional application Serial No. 61/970,794 filed March 26, 2014, herein incorporated by reference in its entirety.

10 **SEQUENCE LISTING**

The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on March 22, 2015, is named U of Maryland and is 16,384 bytes in size.

15

BACKGROUND OF THE INVENTION

Modification of animal genomes has multiple uses. Where a gene is modified, by, for example, silencing the gene, prohibiting the expression of protein, changing expression product or expression levels, the function of the gene or region of the gene becomes
20 apparent. Changes to the gene may also result in modification to a more desired phenotype. Treatment of disease is also possible, where defective genes can be modified. Effective gene targeting of animals and in particular large domestic animals in which the pronuclei are difficult to visually identify in a fertilized zygote has numerous challenges preventing reliable delivery of targeting constructs in order to effectively target a specific
25 region in such animal genome.

SUMMARY OF THE INVENTION

The present method allows for injection of nucleic acid molecules into zygotes of large animals followed by incorporation of the nucleic acid molecule into the nucleus of
30 the cell, such that one need not visually identify the pronuclei of the zygote. The method provides for injecting nucleic acid molecules into the zygote after fertilization of an egg by sperm and prior to formation of a pronucleus. Methods in one embodiment employ

homologous recombination with the resulting nucleus that is formed having the nucleic acid molecule of interest targeted. A double stranded break may be induced at the target locus in an embodiment of the invention. A nuclease and either single stranded oligonucleotides or a double stranded targeting vector is provided with heterologous nucleic acid molecules of interest and sequences having homology to sequences flanking the site of the double stranded break, which allows for homologous recombination at the site. In an embodiment, the flanking sequences may be 50 base pairs (bp) or more when using single stranded oligonucleotides, and may be 500 bp or more when using a double stranded targeting vector. The method may be used for modifying expression of sequences in the animal by, for example, inhibiting expression, deletion, replacement of alleles, or introducing into the animal genome a sequence, which in one embodiment expresses a unique protein.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a photomicrograph of porcine and murine zygotes.

Figure 2 shows CRISPR-mediated knockin of GFP transgene into the *PRNP* locus.

A) is a schematic drawing of the targeting vector showing targeting arms homologous to endogenous *PRNP* locus. The term “upper” refers to the 500 bp of the targeted *PRNP* locus upstream of the cleavage site and “lower” refers to the 1000 bp of the downstream flanking sequence. UBC refers to (human ubiquitin C promoter), GFP refers to green fluorescent protein; bPA (bovine poly adenylation transcription terminator sequence); PGK/EM7 – is a hybrid eukaryotic (phosphoglycerol kinase) and prokaryotic (EM7, a synthetic bacterial promoter derived from the T7 promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*

patents/US7244609) RNA polymerase II promoter sequences driving the expression of Neo/kan which are neomycin (or G418 for eukaryotic) and kanamycin resistance (for prokaryotic) selectable markers. The linearized targeting vector alongside, Cas9 mRNA and single guide (sgRNA) targeting *PRNP* are injected into the porcine zygotes. B) is a schematic showing an embodiment of the process. Cas9 induces double strand break in 3rd exon of *PRNP*. The broken DNA is then repaired with the targeting vector, resulted in the targeted allele.

Figure 3 A and B are photos showing representative embryos that have developed to the blastocyst stage show expression of GFP, with A) showing the embryo under green fluorescent microscope and B) showing bright field microscope view.

Figure 4 is a gel where use of primers, one within the targeting vector and another outside of the homologous region, shows specific band of right size confirming targeting to the intended locus.

Figure 5A and B show CRISPR mediated homology directed repair and editing of porcine genomes using a single stranded oligonucleotide incorporation into the zygote. A) is a schematic of Cas9 vector, sgRNA targeting *ZBED6* locus and a single stranded oligo containing a LoxP site and a EcoRI restriction enzyme site injected into porcine zygotes. CMV and T7 refer to the promoters HA is HA tag, NLS is nuclear localization signal. B) is a gel showing the PCR amplicon contains the recombined EcoRI site, which can be digested to produce two fragments, confirming the recombination of a functional EcoRI enzyme site.

Figure 6 shows sequencing of the recombined *ZBED6* allele (the entire sequence shown is SEQ ID NO: 13) showing the EcoRI site (underlined) and the LoxP (SEQ ID NO: 11) site in the inset.

Figure 7 shows A) a schematic of the pronuclei with loxP targeting; and two gels, B) a gel showing *ZBED6* with loxP targeting and C) PRNP with loxP targeting.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Transfer of genetic material into mammalian cells was first reported 50 years ago (Szybalska, E. et al. Genetics of human cell line. IV. DNA-mediated heritable transformation of a biochemical trait. *Proc Natl Acad Sci U S A* 48, 2026-2034 (1962)) when cells were made resistant to hypoxanthine, aminopterin and thymidine (HAT) selection medium by calcium phosphate mediated transfection. The efficiency of exogenous transfer was further improved by injection of DNA directly into tissue culture cells with the aid of micropipettes mounted on micromanipulators. (Graessmann, et al. Retransformation of a simian virus 40 revertant cell line, which is resistant to viral and DNA infections, by microinjection of viral DNA. *J Virol* 32, 989-994 (1979); Capecchi, et al. High efficiency transformation by direct microinjection of DNA into cultured mammalian cells. *Cell* 22, 479-488 (1980)). This served as a prelude for injection of

transgenes into the pronucleus (PN) of mouse zygotes (Gordon, et al. Genetic transformation of mouse embryos by microinjection of purified DNA. *Proc. Natl. Acad. Sci. USA* 77, 7380-7384 (1980)) and the production of the first transgenic mice. (Brinster, R.L. et al. Somatic expression of herpes thymidine kinase in mice following injection of a fusion gene into eggs. *Cell* 27, 223-231 (1981)). Soon after the first demonstrated success in generating transgenic mice by PN injection, similar procedures were used to generate growth hormone transgenic pigs. (Hammer, R.E. et al. Production of transgenic rabbits, sheep and pigs by microinjection. *Nature* 315, 680-683 (1985)). The PN injection procedure remains a widely used technique for making transgenic domestic large animals, such as pigs, cattle, sheep, goats, camelids, dogs, cats, etc., however, only 1% of injected zygotes produce stable transgenic founders. (Niemann, H. Transgenic pigs expressing plant genes. *Proc Natl Acad Sci U S A* 101,7211-7212 (2004); Prather, et al. Genetically modified pigs for medicine and agriculture. *Biotechnology & Genetic Engineering Reviews* 25, 245-265 (2008)). In addition to low efficiencies in generating founder animals, the technique is challenging in pig and other large animal models, where the embryo is murky and the pronucleus is difficult to localize for injecting large DNA constructs (Figure 1).

Besides PN injection, other methods for generating transgenic animals have been attempted, which included sperm-mediated gene transfer, oocyte transduction, and transposons, with varying degree of success. (Park, et al. Role of stem cells in large animal genetic engineering in the TALENs-CRISPR era. *Reprod Fertil Dev* 26, 65-73 (2013)). Specifically in conjunction with the use of CRISPR/Cas system or other site specific nucleases, such DNA constructs can be targeted to a specific region of the gene, allowing for site-specific knockin of the candidate genes, modification of nucleotides or replacement of alleles. However, all the methods suffer from somewhat similar limitations, including (but not limited to): (1) random integration in the genome; (2) insertional mutagenesis; (3) positional silencing; (4) lack of control over the number of integrants and expression; (5) an inability to pre-screen for stable integrations before embryo transfer; and (6) the inability to delete endogenous genes (i.e. gene “knockout” or “KO”, where the gene expression is inactivated or inoperative). “Gene targeting”, whereby the intended gene sequences can be targeted for deletion, or exogenous DNA incorporated, offsets all the disadvantages described above.

Success in gene targeting can be attributed to the discovery that flanking homologous isogenic sequences combined with a positive and negative selection scheme facilitates the creation and identification of recombination events at the intended locus (Luciw, et al. Location and function of retroviral and SV40 sequences that enhance biochemical transformation after microinjection of DNA. *Cell* 33, 705-716 (1983); Kucherlapati, R.S. et al. Homologous recombination in monkey cells and human cell-free extracts. Cold Spring Harbor Symposia on Quantitative Biology 49, 191-197 (1984)). However, one of the major limitations of homologous recombination (HR)-based gene targeting for knocking out genes, introducing point mutations, or knocking-in genes is the poor efficiency of achieving correct recombination events, typically in the range of 1 in 10^6 – 10^7 cells. In addition, these modifications are often monoallelic in nature, requiring a second round of targeting for bi-allelic (homozygous) modifications. In pigs and other livestock species that lack genuine embryonic stem cells (ESC), somatic cells, typically fetal fibroblasts are used for gene targeting, and the modified cells are used as donor cells in nuclear transfer or cloning to generate the genetically modified (GM) animals. The gene targeting efficiencies are relatively poor when using somatic cells as precursors, which is further compounded by the relatively early senescence of the fibroblasts precluding characterization of the desired knock in (KI) or other genetic alterations in the course of the experiment. With the long gestation length and maturation to reproduction age of pigs and other large animals, the generation of homozygous knockin (or “KI”, where a nucleic acid sequence is inserted at a particular locus) animals by nuclear transfer or cloning to produce recombinant pigs is both technically challenging and cost prohibitive.

An improved method is shown here of targeting genome editing in zygotes that allows for genome targeting in animals including animals having a zygote with optical density such that the pronuclei are obscured as a result of lipid granules in the cytoplasm interfering with visualization. This makes it difficult to visually identify the pronuclei of the zygote with the naked human eye and inject nucleic acid molecules into the nuclei. A pronucleus is the haploid nucleus of a sex cell, here the male and female pronuclei present following fertilization of the oocyte (egg) by the spermatatozoa (sperm). The membranes of the pronuclei dissolve and the chromosomes align, then becoming part of a single diploid nucleus and cell division occurs. One skilled in the art appreciates that it is possible to determine the time frame prior to formation of the pronuclei into nucleus.

Using homologous recombination techniques, precise targeting of a nucleic acid molecule to a location of the genome is now possible using direct injection into such animal zygotic cells where the injection occurs after fertilization and prior to the pronuclei forming a nucleus. Using this method it has been found the nucleic acid molecule will be efficiently recombined into the nucleus. One embodiment provides for injection up to 18 to 24 hours after fertilization. In an embodiment the time frame is at up to five hours in one embodiment, and up to 12 hours in another embodiment. At embodiment provides injection occurs at three, four or five hours after fertilization. For about three to five hours after fertilization the cells are typically kept in a fertilization medium, and would be injected after removal from the medium. In a further embodiment injection occurs about up to 16 hours after fertilization, in an embodiment is three to four to five to six to seven to eight to nine to ten to twelve to thirteen to fourteen to fifteen hours after fertilization up to 16 hours, and in further embodiment is 8 to 12 hours after fertilization. This avoids the need to use fetal fibroblasts or a system of nuclear transfer or cloning. A nucleic acid sequence of interest is injected along with components which target the sequence to the desired target locus in the genome and provide for homologous recombination at the site. Such components in an embodiment include a nuclease for cleaving the target locus, along with a guide RNA that directs the nuclease to the targeted locus.

Any method which provides for targeting of the nucleic acid molecule of interest (NOI) to the target site of the target gene may be utilized in the method. The following is provided by way of example rather than limitation. A guide nucleic acid molecule is one that directs the nuclease to the specific cut site in the genome, whether via use of a binding domain, recognition domains, guide RNAs or other mechanisms. The guide nucleic acid molecule is introduced into the cell under conditions appropriate for operation of the guide nucleic acid molecule in directing cleavage to the target locus. A person of skill in the art will have available a number of methods that may be used, the most common utilizing a nuclease to cleave the target region of the gene, along with sequences which will recognize sequences at the target locus and direct cleavage to the locus. Any nuclease that can cleave the phosphodiester bond of a polynucleotide chain may be used in the methods described here. By way of example without limitation, available systems include those utilizing site specific nucleases (SSN) such as ZFNs (Zinc finger nuclease), (Whyte, J.J. et al. Gene targeting with zinc finger nucleases to produce cloned eGFP knockout pigs. *Mol*

Reprod Dev 78, 2 (2011); Whyte, et al. Cell Biology Symposium: Zinc finger nucleases to create custom-designed modifications in the swine (*Sus scrofa*) genome. *J Anim Sci* 90, 1111-1117 (2012)); TALENs (Transcription activator-like effector nucleases) (see, Carlson, D.F. et al. Efficient TALEN-mediated gene knockout in livestock. *Proc Natl Acad Sci U S A* 109, 17382-17387 (2012); Tan, W. et al. Efficient nonmeiotic allele introgression in livestock using custom endonucleases. *Proc Natl Acad Sci U S A* 110, 16526-16531 (2013); Lillico, S.G. et al. Live pigs produced from genome edited zygotes. *Scientific reports* 3, 2847 (2013)), and the CRISPR (Clustered regularly interspaced short palindromic repeats) -associated (Cas) nuclease system (Hai, T., Teng, F., Guo, R., Li, W. & Zhou, Q. One-step generation of knockout pigs by zygote injection of CRISPR/Cas system. *Cell Res* 24, 372-375 (2014)) that have permitted editing of animal genomes such as pig genomes with relative ease. The use of recombinases such as FLP/FRT as described in US Patent No. 6,720,475, or CRE/LOX as described in US Patent No. 5,658,772, can be utilized to integrate a polynucleotide sequence into a specific chromosomal site.

Meganucleases have been used for targeting donor polynucleotides into a specific chromosomal location as described in Puchta *et al.*, *PNAS USA* 93 (1996) pp. 5055-5060. ZFNs work with proteins or domains of proteins binding to a binding domain having a stabilized structure as a result of use a zinc ion. TALENs utilize domains with repeats of amino acids which can specifically recognize a base pair in a DNA sequence. For a discussion of both systems see Voytas et al. US Patent No. 8,697,853, incorporated herein by reference in its entirety. These systems utilize enzymes prepared for each target sequence.

The CRISPR/Cas nuclease system has evolved in archaea and bacteria as a RNA based adaptive immunity system to detect and cleave invading viruses and plasmids.

(Horvath, P. & Barrangou, R. CRISPR/Cas, the immune system of bacteria and archaea. *Science* 327, 167-170 (2010); Wiedenheft, et al. RNA-guided genetic silencing systems in bacteria and archaea. *Nature* 482, 331-338 (2012)). Unlike ZFNs and TALENs, which require assembly of DNA binding domain (DBD) to direct the nuclease to the target site, the CRISPR/Cas system utilizes RNA as a guide. The CRISPR locus is a distinct class of interspersed short sequence repeats (SSRs) recognized in bacterial genes. The repeats are short elements occurring in clusters that are regularly spaced by unique intervening sequences with a substantially constant length. They were observed as an immunity

system in which nucleic acid molecules homologous to virus or plasmid sequences are integrated into the CRISPR loci. The foreign DNA or RNA is targeted and cleaved. The system has been adapted for targeted insertion of a nucleic acid molecule at a defined locus. In general, a CRISPR system is characterized by elements that promote the formation of a CRISPR complex at the site of a target sequence to which a guide sequence is designed to have complementarity, where hybridization between a target sequence and a guide sequence promotes the formation of a CRISPR complex. Full complementarity is not necessarily required, provided there is sufficient complementarity to cause hybridization and promote formation of a CRISPR complex. In the CRISPR system one enzyme, a CRISPR enzyme is used for targeting using short RNA molecules.

Two basic components are used with the system, a guide RNA and an endonuclease. The guide RNA is endogenous sequence specifying the target site and tracrRNA, needed to bind to the enzyme. The guide sequence provides target specificity and the tracrRNA provides scaffolding properties. These guide sequences are typically about 15 up to 20 to 25 base pairs (bp) that hybridize with the target site and direct binding of a CRISPR complex to a target sequence. A sequence encoding a CRISPR-associated enzyme may be provided on the same or different vectors. Non-limiting examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, homologs thereof, or modified versions thereof. In one embodiment the enzyme is a type II CRISPR system enzyme and is Cas9 or variants or modifications thereof. These enzymes are known; for example, the amino acid sequence of *S. pyogenes* Cas9 protein may be found in the SwissProt database under accession number Q99ZW2. The enzyme or Cas9 protein can be used as a nickase or nuclease and cleave one or two strands of DNA. Cas9 has two functional domains, RuvC and HNH and when both are used both strands are cleaved. Cas9 nuclease forms a ribonuclease complex with target CRISPR RNAs (crRNAs) and transactivating RNAs (tracrRNA), and uses the chimeric RNA to target the genomic sequence and induce DSB. The CRISPR/Cas nuclease and other SSN can introduce a targeted double strand break (DSB) in the genomic DNA, which in the presence of a single stranded (SS) DNA oligonucleotide or a double stranded (DS)

targeting vector, result in homologous recombination (HR) based alteration of selected nucleotides or KI of transgenes respectively, into the target loci. In another embodiment a SS oligonucleotide having the nucleic acid molecule of interest may be used with Cas9 mRNA and sgRNA to target modification of a particular target gene region. In further
5 embodiments the target gene is complementary to the gRNA sequence and will have a protospacer adjacent motif or PAM sequence. This aids in binding by Cas9. For a discussion of details of the CRISPR/Cas system see Cong et al., US Patent Nos. 8,932,814; 8,871,445 and 8,906,616, incorporated by reference herein in their entirety.

Breaks in the genome can be repaired by the non-homologous end joining DNA
10 repair pathway (NHEJ) or by homology directed repair pathway (HDR). NHEJ can disrupt the gene, by causing frame shifts or premature stop codons to occur. HDR is an embodiment that provides for insertion of a nucleic acid molecule that avoids such issues. With a double strand break a DNA repair template is provided in which sequences are provided that have homology to and hybridize with genome sequences flanking the
15 cleavage site (homology arm). In one embodiment the DNA template or flanking sequences are transfected into the cell with the CRISPR/Cas vector.

Even though HDR-based gene targeting events are extremely rare, the efficiencies can be improved by several orders of magnitude (>1000-fold) by introducing a DSB at the target locus (Moehle, E.A. et al. Targeted gene addition into a specified location in the
20 human genome using designed zinc finger nucleases. *Proc Natl Acad Sci U S A* 104, 3055-3060 (2007)). Following DSB, either a SS oligo, or a DS vector with homology to the ends flanking the DSB, can produce animals with targeted genomic alterations or transgene integrations (Cui, Let al. The permissive effect of zinc deficiency on uroguanylin and inducible nitric oxide synthase gene upregulation in rat intestine induced by interleukin
25 1alpha is rapidly reversed by zinc repletion. *The Journal of Nutrition* 133, 51-56 (2003); Meyer, M et al. Gene targeting by homologous recombination in mouse zygotes mediated by zinc-finger nucleases. *Proc Natl Acad Sci U S A* 107, 15022-15026 (2010)).

In the inventors laboratory, CRISPR/Cas mediated HDR and editing of nucleotides and gene KI by injections directly into the porcine zygotes bypassing the need for nuclear
30 transfer/cloning to generate genetically modified (GM) animals. The length of each homology arm will vary depending on the size of the modification to the genome. Here, the inventors have discovered far smaller homology arms may be utilized than previously

employed when not using the present method. Previously the sequence homologous to the target gene flanking sequences were required to be of a size in the region of 6000 bp.

However, here with use of a double stranded break and site specific nuclease systems, it is demonstrated the methods need less than 6000bp homologous regions, and operate with
5 only at least about 40 bp, at least about 50 bp and amounts in-between, or more upstream and about 40 bp, at least about 50 bp and amounts in-between, or more downstream sequences for use with single stranded oligo and about at least 300 bp, at least 500 bp up to 1000 bp and amounts in-between or more with a double stranded targeting vector. This provides for a much less laborious process in preparing such sequences, reducing the time
10 for preparation of a target vector to one to two weeks or less instead of six months. These homologous arms are provided with the SS oligonucleotide or DS vector.

The present methods provide for expansion of use in gene editing to provide greater efficiencies, by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, up to 100% increase and amounts in-between in the number of recombination events obtained. The fold
15 increase in events recovered is up to 1000 fold or more. This results in high efficiency and usefulness with large animal gene editing and use in many settings.

In referring to a target gene is meant to refer to any nucleic acid molecule within the animal genome desired to be modified as described or where it is desired to insert a nucleic acid molecule. The target polynucleotide can be a sequence coding a gene product
20 (e.g., a protein) or a non-coding sequence (e.g., a regulatory polynucleotide or a junk DNA).

The process is useful with knockins and knockouts. One can upregulate gene transcription through insertion of a transcriptional activator, for example, or repress expression using transcriptional repressors. Without intending to be limiting, among the
25 variety of utilities of gene editing include modifying (e.g., deleting, inserting, translocating, inactivating, activating, mutating) a target polynucleotide in a multiplicity of cell types. In some embodiments the polypeptide expressed may be modified. There are a broad spectrum of applications in, e.g., gene therapy, drug screening, disease diagnosis, prognosis, increasing or decreasing growth and body composition, and improving quality
30 or composition of animal products. The methods are useful in any situation where modification of a disease gene is desired. Further examples include improved feed use and meat composition, enhanced reproductive performance, changing component content of

animal products such as milk (such as lactose content), and, reduce or eliminate phenotypes such as boar taint phenotype. The process is useful with so-called knockins where a sequence is inserted in the genome or knockouts where gene expression is reduced or eliminated or interrupted. This allows for understanding and control of the gene and its' downstream impact.

The target nucleotide may include a number of disease-associated genes and polynucleotides as well as signaling biochemical pathway-associated genes and polynucleotides. Examples of target polynucleotides include a sequence associated with a signaling biochemical pathway, e.g., a signaling biochemical pathway-associated gene or polynucleotide. Examples of target polynucleotides include a disease gene or polynucleotide. A "disease" gene or polynucleotide includes any gene or polynucleotide associated with impacting disease in and animal and can include a gene or polynucleotide which is yielding transcription or translation products at an abnormal level or in an abnormal form in cells derived from a disease-affected tissues compared with tissues or cells of a non-disease control. A disease gene is any gene associated with an increase or decrease in the risk of having or developing a disease or recovery from disease. It may be a gene that becomes expressed at an abnormally high level; it may be a gene that becomes expressed at an abnormally low level, where the altered expression correlates with the occurrence and/or progression of the disease. A disease gene also refers to a gene possessing mutation(s) or genetic variation that is directly responsible or is in linkage disequilibrium with a gene(s) that is responsible for the etiology of a disease. The transcribed or translated products may be known or unknown, and may be at a normal or abnormal level. A vast array of animal diseases may be treated, prevented or studied by use of the methods here with genes or proteins encoded associated with the disease. A few examples include the *PRNP* gene providing resistance to transmissible spongiform encephalopathies; upregulation of *SOCS1*, *SOD2*, *RBP4*, *HLA-B*, *HLA-G*, *PPP2R1A* and *TAP1* gene or downregulation of *IL18*, *TF*, *C4BPA*, *C1QA*, *C1QB* and *TYROBP* genes of immune response genes in protection from PRRSV; KI decoys to combat zoonotic flu disease, eliminating negative phenotypes such as boar taint, and introgress agriculturally beneficial traits.

A still further example of potential uses provides for introduction into the animal cell of interfering nucleic acid molecules. For example, double-stranded RNA molecules

(dsRNA) may be employed. In this process, in summary, RNA which is double stranded, in part, or completely, is produced based upon the sequence of the target nucleic acid molecule. Specifics of the means of producing the dsRNA may vary as one skilled in the art appreciates, and include, by way of example without intending to be limiting, the

5 approach of Graham et al., US Patent No. 6,573,099 where two copies of a sequence corresponding to a target sequence is used, or that of Fire et al., US Patent 6,326,193 (both incorporated herein by reference), where the first strand is an RNA sequence corresponding to the target nucleic acid, and the second is one which is complementary to the target sequence, each of which are incorporated herein by reference in their entirety.

10 These strands hybridize with each other to form the inhibiting dsRNA. The strand which corresponds to the target nucleic acid molecule can correspond to all or a portion thereof, as long as a dsRNA is formed. Where a strand is used which is the complement (antisense) of the target nucleic acid is used, it can be complementary to all or a portion of the target nucleic acid molecule, so long as the dsRNA formed interferes with the target nucleic acid

15 molecule. The dsRNA triggers a response in which the RNase III Dicer enzyme process dsRNA into small interfering RNAs (siRNA) of approximately 21 - 23 nucleotides, which are formed into a RNA-induced silencing complex RISC which destroys homologous mRNAs. (See, Hammond, S. M., et al., *Nature* (2000) 404:293-296). Generally, sequences of up to 10 nucleotides 20 nucleotides, 30 nucleotides, 40 nucleotides, 50

20 nucleotides, 100 nucleotides, 200 nucleotides, 300, 500, 550, 500, 550, or greater and any amount in-between may be used.

One skilled in the art appreciates there are many uses available and which will become available for the methods described here.

The methods may be used in any animal. They are most useful with animals

25 having pronuclei following fertilization that is at least partially visually obscured, making injection into the pronuclei difficult. Such pronuclei cannot be visually observed by the unaided human eye, that is, with the human eye and where visualized with a microscope, unaided by contrast, or other process to allow visualization. Such animals include "large domestic animals" that is, pigs, cattle, horses, dogs, cats, and other ruminant animals such

30 as sheep, goats, oxen, musk ox, llamas, alpacas, guanicos, deer, bison, antelopes, camels, and giraffes oxen, musk ox, llamas, alpacas, guanicos, deer, bison, antelopes, camels, and giraffes. Livestock animals are among those included in the animals for which the

processes can be used. Besides, in other animal models in which the cytoplasm is clear such as primates, rabbits, minks and other models, the procedure is still an attractive option, as it allows for not having to guess when the pronuclei are being formed, and instead the material can be injected into the cytoplasm.

5 The methods are particularly useful with swine. Pig is an economically important agricultural animal. Additionally, pigs are coveted for their biomedical applications. Similar to humans and mouse, the pigs are mono-gastric, and as such are playing a dominant role in investigations of nutrient uptake, trafficking and metabolism. (Patterson, et al. The pig as an experimental model for elucidating the mechanisms governing dietary
10 influence on mineral absorption. *Experimental biology and medicine* 233, 651-664 (2008)). Advances in the field of animal genome editing have included sequencing of pig genome. (Groenen, M.A. et al. Analyses of pig genomes provide insight into porcine demography and evolution. *Nature* 491, 393-398 (2012)). Taken together, depending on the biological question that needs to be addressed, a suitable pig model is available for investigation.
15 However, until now there has been a lack of incentive for the use of pig as “preferred models”, due to the GM technologies that lag behind the mouse models. The present methods address these shortcomings.

 In recent years, there is an increasing consensus that the mouse, although still a powerful genetic model species, has limitations and cannot fulfill the full spectrum of
20 biomedical demands to address preventative medicine (obesity, infertility, cardiovascular disorders), identification of new or improved diagnostics, and models of farm derived zoonotic diseases. As an alternative, large domesticated animals such as pig are gaining favor, because they are more similar anatomically, physiologically, and immunologically to humans, while maintaining the advantages of being a litter bearing species and a
25 relatively long life span permitting long term investigations. Examples where the mouse model has not met expectations due to differences in anatomy or physiology include, cystic fibrosis, ocular and cardiac diseases. (Rogers, C.S. et al. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. *Science* 321, 1837-1841 (2008); Welsh, M et al. Development of a porcine model of cystic fibrosis. *Transactions of the
30 American Clinical and Climatological Association* 120, 149-162 (2009); Zhou, L. et al. Differentiation of induced pluripotent stem cells of swine into rod photoreceptors and their integration into the retina. *Stem Cells* 29, 972-980 (2011); Whyte, J.J. et al. Vascular

endothelium-specific overexpression of human catalase in cloned pigs. *Transgenic Res* 20, 989-1001 (2011)). As almost all domestic pigs are crossbreeds, the resulting phenotype from these animal models is more reliable and applicable to the human diseases than inbred mouse strains. Likewise, the domestic pigs are better suited for zoonotic or infectious disease research, where they serve as reservoir or carriers of the disease, or are natural hosts to the pathogen. In addition to serving as models of human disease, the domestic pig is coveted for studies where the relatively long life span, close similarity in body size and physiology to humans offer an advantage. Briefly, pigs are preferred models for nutritional studies.

In referring to injection is meant any convenient method of inserting a device into the cell and passage of the nucleic acid molecules into the cell. By way of example without limitation, this can be accomplished with an injection pipette which may include a syringe holding the nucleic acid molecules. The pipette is inserted through the zona pellucida. Contrary to present techniques, one need not be able to visually observe the pronuclei in order to contact the injection device with the pronuclei. Instead, one need only introduce the nucleic acid molecules into the fertilized oocyte, without concern if the pronuclei are contacted, and introduction into the cytoplasm is sufficient. The injection occurs after fertilization and prior to the pronuclei forming a nucleus. Prior to fertilization, the female DNA will be at metaphase II stage and not have completed meiosis. The sperm stimulates meiosis and eventual formation of a nucleus. Here injection occurs before the nucleus forms. An embodiment provides the injection occurs up to 16 hours and, in an embodiment, 12 to 16 hours after fertilization, in another embodiment three, four, five or 6 to 12 hours after fertilization and in a further embodiment 16 hours after fertilization. As noted herein, one skilled in the art can determine when, in a particular animal, the nucleus will be formed and inject prior to that time. In pigs and cows for example, the time frame is 12 to 16 hours after fertilization. Without wishing to be bound by any theory it is believed this provides sufficient time to dissipate the molecules in the cytoplasm and for the nuclease recombination components to integrate the nucleic acid molecule into the eventual nucleus. Not only does this allow for introduction of nucleic acid molecules into large animals in which injection of the pronuclei was difficult, but also provides high event recovery, here, up to 100%, and avoids problems with production of a mosaic which can occur if recombination occurs after DNA replication.

As used herein, the terms nucleic acid or polynucleotide refer to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form unless indicated otherwise. As such, the terms include RNA and DNA, which can be a gene or a portion thereof, a cDNA, a synthetic polydeoxyribonucleic acid sequence, or the like, and can be single-stranded or double-stranded, as well as a DNA/RNA hybrid. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g. degenerate codon substitutions) and complementary sequences as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al. (1991) *Nucleic Acid Res.* 19:5081; Ohtsuka et al. (1985) *J. Biol. Chem.* 260:2605-2608; Rossolini et al. (1994) *Mol. Cell. Probes* 8:91-98). The term nucleic acid is used interchangeably with gene, cDNA, and mRNA encoded by a gene.

A "polypeptide" refers generally to peptides and proteins. In certain embodiments the polypeptide may be at least two, three, four, five, six, seven, eight, nine or ten or more amino acids or more or any amount in-between. A peptide is generally considered to be more than fifty amino acids. The terms "fragment," "derivative" and "homologue" when referring to the polypeptides according to the present invention, means a polypeptide which retains essentially the same biological function or activity as said polypeptide. Such fragments, derivatives and homologues can be chosen based on the ability to retain one or more of the biological activities of the polypeptide. The polypeptides may be recombinant polypeptides, natural polypeptides or synthetic polypeptides.

Thus when referring to a nucleic acid molecule of interest (NOI) is meant a nucleic acid molecule which is desired to be introduced into the animal cell nucleus. An NOI, then, by way of example without limitation, may be the target gene and may be modified; RNA; interfering RNA; a nucleic acid molecule that can have various impact on the target gene or another gene, as discussed herein; a nucleic acid molecule newly inserted into the genome and that may produce an additional polypeptide within the genome, or a combination of any of these. Any nucleic acid molecule desired to be introduced into the animal cell genome can be the NOI.

"Codon optimization" can be used to optimize sequences for expression in an animal and is defined as modifying a nucleic acid sequence for enhanced expression in the cells of the animal of interest, e.g. swine, by replacing at least one, more than one, or a significant number, of codons of the native sequence with codons that are more frequently
5 or most frequently used in the genes of that animal. Various species exhibit particular bias for certain codons of a particular amino acid. Cas9 can be one of the sequences codon optimized for improved expression.

In one aspect, polynucleotides comprising nucleic acid fragments of codon-optimized coding regions which may produce RNA, encode polypeptides, or fragments,
10 variants, or derivatives thereof, with the codon usage adapted for optimized expression in the cells of a given animal. These polynucleotides are prepared by incorporating codons preferred for use in the genes of the host of interest into the DNA sequence.

A "heterologous" nucleic acid molecule is any which is not naturally found next to the adjacent nucleic acid molecule. A heterologous polynucleotide or a heterologous
15 nucleic acid or an exogenous DNA segment refers to a polynucleotide, nucleic acid or DNA segment that originates from a source foreign to the particular host cell, or, if from the same source, is modified from its original form in composition and/or genomic locus by human intervention. A heterologous gene in a host cell includes a gene that is endogenous to the particular host cell, but has been modified or introduced into the host.
20 Thus, the terms refer to a nucleic acid molecule which is foreign or heterologous to the cell, or homologous to the cell but in a position within the host cell nucleic acid in which the element is not ordinarily found.

A nucleic acid may then be introduced into an animal host cell through the use of a vector, plasmid or construct and the like. A "vector" is any means for the transfer of a
25 nucleic acid into a host cell. Vectors can be single stranded, double stranded or partially double stranded, may have free ends or no free ends, may be DNA, RNA or both. A variety of polynucleotides are known to be useful as vectors. A plasmid is a circular double stranded DNA loop. Referring to one or more expression vectors is meant to refer to one or more vectors comprising necessary regulatory elements for proper expression of
30 the operably linked nucleic acid molecules. A vector may be a replicon to which another DNA segment may be attached so as to bring about the replication of the attached segment. A replicon is any genetic element (e.g., plasmid, phage, cosmid, chromosome, virus) that

functions as an autonomous unit of DNA or RNA replication *in vivo*, i.e., capable of replication under its own control. The term "vector" includes both viral and nonviral means for introducing the nucleic acid into a cell *in vitro*, *ex vivo* or *in vivo*. Viral vectors include but are not limited to adeno-associated viruses, lentiviruses, alphavirus, retrovirus, pox, baculovirus, vaccinia, herpes simplex, Epstein-Barr, rabies virus, and vesicular stomatitis virus. Non-viral vectors include, but are not limited to plasmids, liposomes, electrically charged lipids (cytofectins), DNA- or RNA protein complexes, and biopolymers. In addition to a nucleic acid, a vector may also contain one or more regulatory regions, and/or selectable markers useful in selecting, measuring, and monitoring nucleic acid transfer results (transfer to which tissues, duration of expression, etc.). Transformed cells can be selected, for example, by resistance to antibiotics conferred by genes contained on the plasmids, such as the *amp*, *kan*, *gpt*, *neo* and *hyg* genes. The techniques employed to insert such a sequence into the viral vector and make other alterations in the viral DNA, e.g., to insert linker sequences and the like, are known to one of skill in the art. (See, e.g., Sambrook et al., 2001. Molecular Cloning: A Laboratory Manual, 3rd Edition. Cold Spring Harbor Laboratory Press, Plainview, NY). A "cassette" refers to a segment of DNA that can be inserted into a vector at specific restriction sites. The segment of DNA encodes a polypeptide of interest or produces RNA, and the cassette and restriction sites are designed to ensure insertion of the cassette in the proper reading frame for transcription and translation.

The nucleic acid molecule may be operably linked to a suitable promoter at the 5' end and a termination signal and poly(A) signal at the 3' end. As used herein, the term "operably linked" means that the nucleic acid molecule containing an expression control sequence, e.g., transcription promoter and termination sequences, are situated in a vector or cell such that expression of the polypeptide or RNA produced by the nucleic acid molecule is regulated by the expression control sequence. Methods for cloning and operably linking such sequences are well known in the art. Promoters may direct constitutive expression or tissue preferred expression. Tissue-preferred (sometimes called tissue-specific) promoters can be used to target enhanced transcription and/or expression within a particular cell or tissue. Such promoters express at a higher level in the particular cell region or tissue than in other parts of the cell or tissue and may express primarily in the cell region or tissue. Examples include promoters that secrete to the cell wall, retain expression in the

endoplasmic reticulum, or target vacuoles or other cell organelles. Other may direct expression primarily to muscle, neuron, bone, skin, blood or specific organs or cell types. Such promoters may also direct expression in a temporal manner, expressing at a particular stage of development or cycle of the cell. The promoter(s) utilized in one example may be
5 polymerase (pol) I, pol II or pol III promoters. Examples of pol I promoters include the chicken RNA pol I promoter. Examples of pol II promoters include but are not limited to the cytomegalovirus immediate-early (CMV) promoter, the Rous sarcoma virus long terminal repeat (RSV-LTR) promoter, and the simian virus 40 (SV40) immediate-early promoter. Examples of pol III promoters includes U6 and H1 promoters. Inducible
10 promoters may be used such as the metallothionein promoter. Other examples of promoters include, T7 phage promoter, T3 phage promoter, beta-galactosidase promoter, and the Sp6 phage promoter. An example of a DNA having a termination and poly(A) signal is the SV40 late poly(A) region. The use of these commercially available expression vectors and systems are well known in the art. The vector may contain multiple copies of a nucleic acid
15 molecule of interest or a combination of nucleic acid molecules; also multiple vectors may be introduced simultaneously or sequentially into the cell.

Other components may be included in the vector or in vectors also introduced into the cells, such as polyadenylation sequences, enhancers, signal peptides, inducible elements, introns, translation control sequences or the like. As noted above, selectable
20 markers allowing survival of cells with the vector or other identification of cells having the vector may be used.

A nucleic acid molecule is introduced into a cell when it is inserted in the cell. A cell has been "transfected" by exogenous or heterologous DNA or RNA when such DNA or RNA has been introduced inside the cell. When referring to integration of a nucleic acid
25 molecule into a cell is meant that the molecule has recombined and become part of the genome.

The presence of the nucleic acid molecule of interest may be determined by any convenient technique, such as identifying the presence of a marker gene; detecting the presence of the inserted sequence via PCR or the like; detecting expression product from
30 animal cells, tissue or fluids; Northern or Western blot analysis; or any other readily available method.

All references cited herein are incorporated herein by reference. The examples presented are provided by way of illustration and not meant to limit the scope of the invention.

5

EXAMPLES

CRISPR mediated gene knock-ins:

In the inventors' laboratory, major prion protein (*PRNP*) has been used as a so-called "safe harbor" locus for targeted KI of transgenes. In mouse, transgenes are typically knocked into the *Rosa26* locus, which is ubiquitously expressed in all target tissues, and has been shown not to be vital for the survival of offspring if deleted. (SEQ ID NO: 1 is the *PRNP* protein Gene ID: 494014) Therefore, *Rosa26* has been the preferred site for inserting transgenes to prevent both: a) inadvertent silencing of the transgene; and b) insertional mutagenesis caused by random insertion of a transgene into an off-target site in the genome. In mouse, besides *Rosa26*, *PRNP* is another ubiquitously expressed gene, and is not required for viability, thereby qualifying as a safe harbor locus. Such a safe harbor gene is one that meets the criteria of having no known adverse effect on the cell by introduction of the vector or nucleic acid molecule into the site and has transcriptional competence across cell types. Besides mice, *PRNP*^{-/-} cattle are also healthy. (Richt, J.A. et al. Production of cattle lacking prion protein. *Nat Biotechnol* 25, 132-138 (2007)). Any safe harbor gene may be utilized as desired for knockin of a nucleic acid molecule.

In pigs, and other large animals, the *Rosa26* locus has not been characterized adequately. Hence, *PRNP* was selected as a safe harbor locus for targeted KO and KI of transgenes and establishing recombinant pigs. The results are discussed below.

25 ***A) Assembly of targeting vector:***

A gene targeting vector was generated consisting of 500 bp upper arm and 1000 bp lower arm homologous to the Cas9 cut site (SEQ ID NO: 2 and 3 respectively) bordering exon-3 of *PRNP* gene. Using primers bearing unique restriction sequences *AscI* and *XhoI*, 1000 bp of sequence of upper arm was cloned into the corresponding sequences in the GFP (green fluorescent protein; see SEQ ID NO: 4 and GenBank U73901) expressing piggyBac vector. (SEQ ID NO: 5, 6,) Likewise, using primers consisting of *BsiWI* and *MluI*, 1000 bp of sequence downstream of the cut site were amplified and cloned into the

same GFP piggyBac vector. (SEQ ID NO: 7, 8). The final targeting vector is generated by digesting the vector with AscI and HpaI and the linearized vector without prokaryotic sequences is injected into the embryos.

5 **B) CRISPR mediated targeted gene knock-in in porcine embryos:**

We investigated whether the gene targeting can be achieved by direct injections into the embryos thereby avoiding the need for targeting in an intermediate cell type and generating GM animals by cloning experiments. As noted in Figure 2a and 2B, by coinjection of targeting vector and CRISPRs (for generating DSB), we have demonstrated
 10 successful KI of GFP transgene into *PRNP* locus in embryos. In Figure 2, UBC refers to (human ubiquitin C promoter), GFP refers to green fluorescent protein; bPA (bovine polyadenylation transcription terminator sequence); PGK/EM7 – is a hybrid eukaryotic (phosphoglycerate kinase) and prokaryotic (EM7, a synthetic bacterial promoter derived from the T7 promoter that enables the constitutive expression of the antibiotic resistance
 15 gene in *E. coli* patents/US7244609) RNA polymerase II promoter sequences driving the expression of Neo/kan which are neomycin (or G418 for eukaryotic) and kanamycin resistance (for prokaryotic) selectable markers. In the figure “Upper” refers to the upper 500 bp homologous sequences flanking the Cas9 cut site, and the “lower” refers to 1000 bp downstream sequences flanking the cleavage site.

20 Briefly, maturing oocytes from sows were purchased from ART Inc. (Madison, WI) and shipped to the lab overnight in their commercial maturation medium #1. Twenty-four hours after being placed in the maturation medium #1 (provided by ART), 50 to 75 cumulus-oocyte complexes (COCs) were placed in 500 µl of tissue culture medium 199 (TCM 199) containing 0.14% PVA, 10 ng/ml epidermal growth factor, 0.57 mM cysteine,
 25 0.5 IU/ml porcine FSH, and 0.5 IU/ml ovine LH and cultured for an additional 20 hours at 38.5°C and 5% CO₂ in air, 100% humidity. (Abeydeera, Let al. Maturation in vitro of pig oocytes in protein-free culture media: fertilization and subsequent embryo development in vitro. *Biol Reprod* 58, 1316-1320 (1998)). COCs were vortexed in 0.1% hyaluronidase in HEPES-buffered medium containing 0.01% PVA for 4 minutes to remove the cumulus
 30 cells following maturation. Groups of 30-35 mature, denuded oocytes were placed in 100 µl of a modified Tris-buffered medium (mTBM) and fertilized according to established protocol (Abeydeera, L.R. & Day, B.N. Fertilization and subsequent development in vitro

of pig oocytes inseminated in a modified tris-buffered medium with frozen-thawed ejaculated spermatozoa. *Biol Reprod* 57, 729-734 (1997)) using fresh extended boar semen. 1-2 ml of extended semen was mixed with Dulbecco's Phosphate Buffered Saline (DPBS) containing 1 mg/ml BSA to a final volume of 10 ml and centrifuged at 1000xg, 5 25°C for four minutes; spermatozoa were washed in DPBS a total of three times. After the final wash, spermatozoa were resuspended in mTBM medium and added to oocytes at a final concentration of 5×10^5 spermatozoa /ml, and co-incubated for 5 hours at 38.5°C and 5% CO₂. Five hours following fertilization, the presumptive zygotes were injected with 100 ng/ul of Cas9 mRNA alongside 50 ng/ul sgRNA targeting PRNP, and 2 ng/ul of 10 linearized targeting vector using Eppendorf Transjector. Approximately, 50 nl of the mixture is injected into the porcine zygotes, and cultured in porcine *in vitro* culture PZM3 medium (Yoshioka, K et al. Birth of piglets derived from porcine zygotes cultured in a chemically defined medium. *Biol Reprod* 66, 112-119(2002)) for 6 additional days. The injected embryos, which have now grown to blastocyst stage were screened for the 15 expression of inserted GFP cassette. In Figure 3A and 3B, expression of GFP was apparent in the expanded blastocysts at day 6 of *in vitro* culture.

Targeted integration of GFP was also confirmed by PCR amplification of blastocyst DNA using primers both within and outside the targeting vector (Figure 4). (SEQ ID NO: 9, 10) A final confirmation was obtained by sequencing of the PCR 20 amplicon. We have performed transfers of these GFP KI embryos to recipient sows and the animals are pregnant at day 60 of gestation, and will likely give rise to the birth of live animals.

Single stranded oligo mediated genome editing in embryos:

25 With the sequencing of animal genomes it is now possible to identify quantitative trait loci (QTL) and in some cases quantitative trait nucleotides (QTN) that can influence the phenotype in question. It is imperative that these QTL and QTNs be tested. The ability to specifically alter nucleotides to accurately reflect superior or disease genotypes will be a powerful approach for improving animal agriculture and for generating disease models 30 respectively. We have investigated if it will be possible to alter nucleotides to obtain desired phenotypes. This approach has the most direct applicability to animal agriculture

where the negative traits such as boar taint, horned phenotype, disease susceptibility, and other parameters be altered with pinpoint accuracy to benefit the animals.

We have tested if specific loci can be targeted for introducing nucleotides by using single stranded oligo bearing the desired nucleotide modifications. In this case, we have investigated if we can target the *PRNP* loci to modify one of the existing nucleotides to generate a novel *EcoR1* restriction enzyme (Figure 5A). The promoters used were CMV and T7, HA refers to _HA tag, NLS is the nuclear localization signal which may be used to facilitate nuclear localization. In addition, for ease of analysis, a 34 nucleotide *LoxP* site (SEQ ID NO: 11 has been engineered on the oligo (Figure 5A). As shown in Figure 5B, we were able to alter a candidate *ZBED6* locus by injecting the *LoxP* and *EcoR1* restriction enzyme bearing oligo, along with Cas9 mRNA and sgRNA targeting *ZBED6*. (SEQ ID NO: 12). *ZBED6* is a zinc finger protein that regulates expression of the insulin-like growth factor 2 gene in pigs. See Markljung et al., “ZBED6, a novel transcription factor derived from a domesticated DNA transposon regulates IGF2 expression and muscle growth. *PLoS Biol.* 7(12) e1000256. As mentioned above, the engineered *ZBED6* locus could be visualized by a 34 nucleotide increase in the length of the PCR product, which was then verified by *EcoR1* digestion. A final confirmation was evident from the sequencing of the targeted loci where the restriction site is shown as underlined (Figure 6). We were able to repeat the results with *PRNP* (See Figure 7. Cas9 was introduced at 100 ng/ul; sgRNA at 50 ng/ul and *LoxP* oligo at 2ng/ul)

We have established a very efficient way for generating transgenic and/or edited animals, by eliminating intermediate steps and performing gene targeting directly in the embryos. The advantages with our approach are two-fold, one in generating targeting vectors and second in delivery of constructs. In terms of the targeting vector, a principle advantage is the less stringent requirement for lengthy homology arms in the targeting construct. In our experiments, gene targeting could be achieved with as small 300, up to 500, up to 1000 bp of homology on each targeting arm, a DNA fragment that is readily obtained by PCR of genomic DNA or can be synthesized as a G-block and obtained from IDT Inc. (Figure 2A). This is in stark contrast to at least 6 kb of homology required for gene targeting in porcine fetal fibroblasts (PFF). In terms of delivery of the DNA constructs, we have identified a window of time post fertilization, where DNA and the CRISPR/Cas can be injected into the cytoplasm of the primitive pig zygote that allows the

DNA to become packaged in the pronucleus when the nuclear envelopes are formed, thereby allowing for homologous recombination mediated gene targeting in the embryos. This strategy eliminates another major bottleneck in generating transgenic animals in pigs where locating pronucleus in the zygote for injecting transgenes has been a limiting factor. Additionally, the efficiencies of gene targeting were 80 to 100% with all of the blastocysts screened, showing accurate targeting of a KI construct in embryos. A final advantage is the ability to edit only few nucleotides precisely in the embryos, which have the ability to alter phenotype for agricultural applications, and for generating biomedical models. In summary, we have developed technologies to usher large animal biotechnology into the genomics era.

LIST OF SEQUENCES

SEQ ID NO: 1 the PRNP protein

NCBI Reference Sequence: NC_010459.4

15 ACGTACGCGGCCAAAAAGAGTCTCAACTCCCTCCCAGAGACTCAGATTTCGACCAGCTTGGCAGATCCCG
GGCGCCGAGCGCCAGAGCGCGCGCGCGCGCCGCCCGCCTCCCTTCCCCGCCGCGCGCCTCGCCACC
CCTCGGCGCCAGACACTGACAGCCCCGAGCTGCGAGCGTCTTCTGTTCCAGCGGTGGCAGGTAAACAGC
CGGGTCGCCCCGAGAACTGGGGGTGCCAAGGTCGGGAGTCAGAACCCCCGCCTTGGAGCTTAGGCGCAA
GGGTGAGCGGCCCCACTTGGGGCGCTAGGAAACCTTGACAGAGAGGGGGGCGGGGGACTTCCGGCGGGCG
20 GGGGGCGCGACAGGCCTGCCCCGCTTGTTCGTGCGCTTAACATTGGCCCCGCTCACATTTGCTTTCCAG
GTGGGGTGAGGGCCCTTTACTCGGAATGGGGCTTGGTGGGGGAAGGGGGTGCTGGGGCTGGCCGCGACC
CCTGGGCAGGGAGGCGGATGGTGGCGGGGAGTCTAGCCCTCTCCACGCGCGTCCGCGGCTGGCGGAGGA
TGGGAGAGGCGCGCCGGCACCGGGGCCGAGGGCCGGGAACCAAGGAGGGTCGCCCACGGCCTCCGCTG
AGGCGCTCGGAGGAGAACCAGGGAGAGGGGCCGCGTGC GGCTCTCCGAGGCCCCAGGGGCACGTGGGG
25 TGGGGATGATGGCCCCGNNN
NN
GGGGTGATGGCCCAGGCCCCGGCGGGAGGGGCCCTTGCCGCCGCCACCATGGAGCTCCTCCGAGAGACG
GCCACCTGCCATCCACGCGGCCCGGGGTGCTGGGGAGGCCGAGCGGGGTGGGCCTCCTGCATCCCTG
GGGATGGAGACCGGGCACGTGGTCCGACCTTCGGGCCTCGGCGGGCGGAGTCTCGGGCGGCCCCACCCTC
30 ACTGTCGGCCGAGACGTCCAGGTCCCTGGGGGCCGAGTGTCCGAGAGCCCAGGTGCTTTGCTTTTCACT
GTCTCCACTGCCCCCTCCCCGAAGGGAAC TGGGCGGT CAGAGGCTCCTCTCAAGGGGATCAGGGCCGACA
GCTCTCCTCCTGATCCACTTGTGTGGGTGCCCTTTCAGGCTTGATTGTAAACAACGAGGAGAAGTCCAT
TTTTACTGTCCCTTTTCATTTTTTTCCCTTTTCTAAATTTGTAGCAACCATGGCAAATCAGTTTTTAAAA
TCATAACCCACAGCCATCAATCCACCCTTACCATCTCAAAGCCACTGCTTTCTGTTTTTCAGTTTTCTGT
35 CTCCAGATTTCGTACATAACGCAAAGAAATTTCAACTGCCCTGATTATGATTATCCTCCTCTAATGGCCGA
GTTATTTTCTTCTGCTTAAAGCGTCGCAGTTTAATAAGCAGTTCGCCGAATGCTGAACATTTGAAATGTT

TCGTTTTTCTTGCAAAAAAACCTTCCAGGTATAACAGTATTAAAGAAAGAATAGGAATAGGAGTTCCCT
GGTGGCCTGGTGGTTAAGGATCCCATATTGTCGCTGCTGTGGCTAGAGTTCCATCCCTGGCCCGGAAACT
TCTGTATACCTCAGGCAAGCCAACAAAAAGAAAAAAGAAGGGAAGAAAAGAAAAAATAGTAACAGAAA
ATTGAATTAAAAATGTCAAACCCCTGGAAAAATTAACAACCTATCTCAGATTTGAGGAAGAAAAAAAATC
5 AACAGTTTTTACCTGCAGTAAACACTGAGGCGCTCTTACAATGAAAAAGAACTAACC GGAAAGGGAAAGAA
AGCAGAGCTAGGATGTGATTTGTATATGATTTGTATCTGACACAAAATTTTCATAGTTATGAAAGGAAAA
TATGAAAAATTATAATAAATGATGAATCAATTATAGAATAAAATGTAAATTAAAGCACTCTGGATTATCAT
TTTACAATTACTAACAAATACAACAACAGTAATAGTAACAGCAACCCTGTTGGAAGATTGCCTAGAAAT
TTTCACATTCAGTTATTTTGAGAGGTGGCAGGACTTTGGGGTTAGAAGAATGGCTCTGCACCTAATTTCA
10 TAGCATGGAATGGGTTACCTAATTTCCCTCATCCTCCTTTTGTGCATTCTATAAAATAGAGGAAATTATACC
TACTTCAGGAAATTGCTAAGATTAAACCATCTATGTAAAACCTGACCTTTGGTATGTAATCCTTTTTCTATT
CTTGGGCACACTGCACTGGGGACATTGTGAATTTACTGTAAAGCAATTTGGTAATGCATTAGGCCATGAC
CCAGAATTTACCTGCAATGGAAGAAAACAACAAGAAAAAAGGGGGGAAAAAAGCCATATGCAGTCA
CAGAATTCAGAATGATCTAAAAATTAGACCCAACGGAAAAACAACCTAAATGTATAACAGCAGGGCAGCAG
15 CTGAGGAAATCATGGCTCTTTAACTGAAAGAAACATTATGTAACCTATCAAAAGTCGGTGGTACATGAGAA
AAAACTGATAAATCAGTGTAGATTACATTACCAAACCTGTATCTACTTACTCAGTGAATGCATATGTGGAA
AATCTGAAAGGAAAAAGCATACAAAGGAATTGAATAGAATTAAAAATGAAGTTAGAAATTATGGGTCAGTTT
AATTTTCTTTTTTATTTATATACTGCTTTTCTAAGTAACGAAATTTTTTAAGATAATTATTCATCGTTCTC
AATTTTTGTAATGAAATGGAGCCATAGTTTTCTGTATGTGGGAGAGGGAGAGCTCAGTGTATGTTAGCT
20 GACTTCATTTCTTCAGATATTGTCTCTTTTTTTTTTCTCGTGTAGATGGATTAGGGGGTTAGTAATGTATA
TATTAGGATCCTTCTTTAAGGAATAGNNTCTAAAAATTATTATCAATTCTAGNTTTTTCTTTTTTTGGTG
TTTCTAAGGACCCTGAATATATTTGAAAACCTGAACAGTTTCAGCTAAGCCGAAGCATTCTGTCTTCCCCA
GAACACAAATCCAGCCTCGCTGAGCCATTACAGATGTACATACTGCAGAGTCCCTTTGATCTCGTGATGG
CTCAGAGTCCCTATCTGTACAGAAAAAGAAGGGCCTAGAAAGGCTATGATGACAGTCCCTTGCTCTGAGGC
25 AACTTAGGGTTATATGTGTAACCCACACCTCTTAAATCATCCTTTCTTGTAATCATTTTGATTTTGCA
GGCAAAGGGCCACGGATTTCTTTAGAATCACTCTGAGTTATACAAGGAATCAACCATTTAAAAAATACAA
TAAAAAAGCAATTACAAATATTTCTGTACCAGATTAACACTGAAGGTGACTATCAGCCAACAAAAGGTTG
ACAGTTTTTCTAAGCTGTGGTTTTAGTTTACCTATTCCATTCTCCCTTTTCAGTTCTTATTTCTATTCC
AAGACAACCTGTATATCAGCTGTGAACTGCTGCATGTGAAACATTCAAACATGCCTCTACATAAAGTGGT
30 GGCTGCTGCAGAAGAATCTGAGTGGATAGCATATATAGCAGTTCTTACAGTGGGAGTATTTTTTTCTCAA
TTTGTTTCATCCTTTTTCTTCTAACTATATTCTGCTTATTGCTGTTCCAGTATTGTGTGATCACATCAAGG
GAGGGGTACCCTGTTATGCTTTATAAGTGTTAAGTTTTGTGCTCCTGGGACCTAGCTCTGAAGCCTGGCT
AGGAGTGCAGTTCTCTGGGAAGCTTTCCCTGTCTTTCCCTGAGCTAAGGTGGAACCTCAGCAGTCATATTTTC
ATCTTTTGAAATCATTTGCTCCCTTAAAGAATCTAATGCAAGCTATATAAAATTTTTACAAACCATTCTGGG
35 GTGGGGGGTTTTTCACTGGCACTCTGAGACTTAGCCCTCGACTGAATAGGGCAAGGGGCCCCAACCTGGC
CATCCTCAGAAATAGGTGAAGAGCTTTTTAAAAATGTAACATTGCTAGAACCTATCCCAGGCTGACAGCCA
GGTGTTTTCTAGTGATGGGATTTAGGAATCTATATTGTAGCAGGATTTAACAGTATCTGATAACAGTATA
TTCTCTCTTCTTTCTTCTTCTTTTTTAAAGTTGAGTTTGTATTGTACACATTCTTACCCCTTATGGT
TTTATTGAACTCAAAAAAATTGAGCTGGAGTTTTGTCATTTTATTGAGATTATAAATTCATTAGGGGTA

ACTGACATCTTTAGAATACTAAATTGTTCCAACCAAGACTTTCCCATTTTTATGGGTCATTTTCTTTTTT
TTTCTTTTTTTTTTTTAAATTTTTTTTTTTTTTTTTTTTTTTTTTTTGGCCTTTTTTGTCTTTTGTGTG
TTGCTATTTCTTGGACCGCTCCCGCGGCATATGGAGGTTCCAGGCTAGGGGTCGAATCGGAGCTGTAGC
CACCGGCTACGCCAGAGCCACAGCAACGGTGGATCCGAGCCGCGTCTGCAACCTACACCACAGCTCACG
5 GCAACGCCGGATCGTTAACCCTAGAGCAAGGGCAGGGACTGAACCCGCAACCTCATGGTTCCTAGTCGG
ATTCTGTTAACCCTGCGCCACGACGGGAACCTCTTTATGGGTCATTTTCTATCTTCTTTATTAATGTTTA
AATTTTTTCCCAGTCTTAATTTCTCTTAAGTCAGTCCTAGTTACATTACAGTTCTGGTTGAAATTATGG
CTATTTTATTAATTTTTTTTCTAGTTGATTATTGCTGCTGTAGAGAAATGCTATTGATTTTTATAGGCCA
ATCTTGTATCCCACAACCTTGCCAACTCTAGTACTGAGTCTAGTACTGAAGTCCCCTTGTGGCGCAGGG
10 GGTAAAGGATCAGGCATTGCAAGCAGCTGTGGTGCAGGCTGCAATTGCAGAGTGGTTTCAATCCCTGGCC
CAGAAACTTCCACATGCCACAAGTACAGCCAAAACAAACAAACAAACAAACAAACAAACTTGTGTCAGGTCT
GTTGAATTTTTTATGTATATGATCATCCAAATTCCAAATAGTGACAGCTGGAGCTCTTTCCTTGCAAGTTC
TTGCACCAGTTACTTCGTTGCTTACAGCGTTGGAAGGACCTCCAGTCCCATGACAGTTGGCATCCTTGTC
TTGCTTCTGATTTTAAAGGGACTGCATTCCAAAGTTATCTATTAAGTACTGTTTTGTGGTATAATCTTTA
15 TCAAGTTAAGGAAATTCCCTCCTATTCCTGGTCTACTAAAAGTATTTTTTTTTTAGTGATAAATAGATATTG
ACCTTTATCAAATACTTAATGTTTTAAAATGTATCAGAGGATTAGGCCACAGAATGACTGTTTCAGGAGTA
TCTTATATGAAATGTTATAACACAGCCAGGCATTGAGAAACCCAGTCTCCATTCCCAGCAATCTCACTAA
TTAGCATTTTAATCGCAGATATGTCACTTGACTTAGCTGAATCTTGGTGGCCTAATTTGTAGAGTGCAG
ATTGGGATTAAATAATACAAGGTCTTTCTTATTTTATCACAAACAGAGATTTTCCATGGTCTCATTAAGT
20 TTTGAGTCTTCTGGAGTTGCGGCTGTGGCTCAGTGGTAGTGAACCTGACGGGTATCCATGAGGACATGG
TTCAATCCCTGGCCTTCTCAGTGGGTTAAGAATCCAGCCTTGCTGTGAGCTGTGATGTAGGTCACAGAAG
TGGCTTGGATCCTGCGTTGCTGTGGCTGTGGTATAGGCCAGCAGCTGTAGTTCCATTTGACTCCTAGCC
AGGGAATTACTATATGCTGCAGGTGGGGCCCAAGTTTTGAGTCTTCCGTATCCTTAGAAATGAGTCTCTC
CTTCAAAATGTAGTTGTTATTTTTTTATGCTTTTTCATAAGTAGATGTTGCTTTTGTCAATTCTCAACTGGT
25 TTTAAAACGATCCTGTCTTAATATAGTCTATGATTATCCAGCTTTACCTAGTATTCAGTGTTTAAGTACT
AATGGCAACATATGCCTGCTCCCCTTACACACTGTTGCCTGTATCTCCAGACCCTGTTTATTCTCAGCT
CCAGATTCCCCAAGCTAACTGCCTACTTGTCTCTCTTGTCCCACATGCAGCTGGAGGATCGCATTGCCAA
AGCCACACCCCTCATTTGTCTCCCTCCAAATTTGCTCCACCTTCTGTGTTCTGTCTACTCAATTGCCGA
TCTGGAAACTTGGGTACCACCTCGATTCTTCCATACTCTTACTTTCCACATCAAACCTGCAAGCCTTCCAG
30 AAGGTGCTAATCCACCTTGTTTCAGGCCCCCTGAGGTGTTGGAACAGAATTGTGAGCAGTATGGAGGCGAAG
AGTTGAGCCCCATCAGCAAATGGATCCTGGTTAGGTTTATTAAACCGCTAAGCCATGAAGGGAACCTCCTA
ATTGGCATATTTTGTGAGCAGTTTGTGCTGATAATGTTCAAATAAATTTTTATTTACACCAAGACCTTTCAA
AAGGTGTTTCTTGGTGACCTAGCAGGTTAAGGATCCAGGGTTGTAAGTCTATGGCTCGGGTCAGTGCTG
TAGCATGGGTGAGCTTGATCCCTGGCTCTGGGACTTCAGCATGCCATGCGTGCAGCCAAAAAAAAAAAAA
35 AATTTTTTTAATAAATGATAGTAGAAACAAATGAAATATTAAGTACTTTATTTCTTTAATCATTCTTCCT
CTGAATATTATACAATTTAATCTTTAACTCTGAAGGTTATGAAAAATAATTTTATATTTGATGCCACTTT
TATTTGAAGATACCCCTGGTGCTGGGGATAAACTAGTATCAGGGTTATAGCATGTGCCGTTTTTGGTTTT
ATGGCACATGGTGTGTTTTGGAGTAGTACATGGTTTGACATGAGGTCCAGTAGAGTCTGTTTAATGGTCATT
CTATTCTGTGCTTTAATCACTGCCCTTGAACCCAGCACCCAGGGTAAATGACATCTTCAGTCTGAAAG

GATGTTTAATTTGATGAATGTACATTGTTTATTCTTAAGTTATTCTAGCCCTTTTATGTCTTAATATGTG
TCTTTTGCACCAAAAATTAGGAGGAAGTAACTCACTCATGAACACCGAATGCCAACTAAAACCTTATTC
AGTGACTGAGTGACTGTAAATCTTGTGAACACAGACTTTCTTTTTTTTTTTTATTAAAAATGTTCTTTTAA
AAAAAATTTTTTTTGGCCAACCACTCATGGCATGTTTGATCAGGCCAGGGATCAAACCTGAGGCAGAGGC
5 GTAACCAGAGCCACAGCAGTGACAATGCTGAATCCTTAACCTGCTGAGCCACCGGGGAACCTCTGAATGC
AGCCTTTCTTACCCCATTTTGTAGCAGCCTCATTGTCTGCCTATAGAAAGAAAGATGAATTTATAGATGG
GCTTGCAAAATCTTGCATGTTTTCTGTTTCCAAAACTGTTGAGAATTCCTTTGAGGAAATTATTGTAGG
TATTTATATATTAGAGGATATTAATTTCTTTACTTAATAGATACTTATTGTGTACCTGCCCTATACCAG
GCACTGCCCCAAGCCCCCTGAGGATATAGCAGCAAACAAAAGAGACTCATTCCCTGCTTACATTCCCCTCA
10 AGGAAGAAGGACACAAGTCAGCTATTTAAAAATTATTTTCATGATCTCAACACCTACCTGGGGGCTTCACT
TCCAGAGGGGCTGCCAGGTCCCTCAAGGTAGTCCACACAGCAGTTAGGGCCTTGGCTTCACTCCCAGCC
CCAGCCCCCACAAGTGACCGCTCAGGTACAAAGGAATGAGTCTGTGCGTAGAGGGTTCCCTTGGCACAG
GGGCCCTAGGCCCCATAGGTGCTGATAGCCCTCATTATAGCCCCATTAGCAGAGCTGCCAGGGTCCCTAC
AAGAAGGTGCCTGGTTACAAGAATTATTACTTTACTTATTTATGCACCATGTGGAAGTTTCCAGGCTAGA
15 AGTCGAATCAGAGATGTAGCTGCTGGCCTACGCCACAGCCATACCAGATCTGAGCTGCATCTGCGACCTC
ACCACAGCACACGGCAAGGCCAGGGATCGAACCCGCGTCCCTCATGGATACTAATCCATGGCTGGTTTCTG
CTGAGTCATGATGGGAACTCCCAGAATCACAAAAGCTCAAAGCTGTGGCAAACCCACCAGGTGTTTATTG
GTTTTTCCAGTTTAGATACAATGTATCAAGCAGAGGTTATTTTTTACCATAAGCATGTTGCTGGCATTCCA
CCTTTATCTTTTCTAAGAAACAGAGCCAGAAAATTATCTGAAGGTCAAATTTGTCCTTAGAGAAGGAGAA
20 AGAGTTGAGTTAACCCTTCACCTACAGTTGTTTTTGTGTGAAGTGTGTCACAGGAGACAAATGGAGTATA
AAGAACATTACAGCTGATGCCGCTACTATGTTTATTATGCTGCAGACATTAAGTGATTTCAATATAAAC
AGGACACTGACACCCCTCTTTATTTTGTATTTTGCAGATAAGTAATCATGGTGAAAAGCCATATAGGTGGC
TGGATCCTCGTTCTCTTTGTGGCCGCATGGAGTGACATAGGGCTCTGCAAGAAGCGACCAAAGCCTGGCG
GAGGATGGAACACTGGGGGGAGCCGATACCCAGGGCAGGGTAGTCTGGAGGCAACCGCTATCCACCCCA
25 GGGAGGGGGTGGCTGGGGACAGCCCCACGGAGGTGGCTGGGGACAGCCCCACGGAGGCGGCTGGGGACAG
CCCCACGGTGGCGGCTGGGGACAGCCCCATGGTGGCGGAGGCTGGGGTCAAGGTGGTGGCTCCCACGGTC
AGTGGAACAAGCCCAGTAAGCCGAAAACCAACATGAAGCATGTGGCAGGCGCCGCTGCAGCTGGGGCAGT
GGTAGGGGGCCTCGGCGGTTACATGCTGGGGAGTGCCATGAGCAGACCCCTGATACACTTTGGCAGTGAC
TATGAGGACCGTTACTATCGTGAAAACATGTACCGTTACCCCAACCAAGTGTACTACAGGCCAGTGGATC
30 AGTACAGCAACCAGAACAGTTTTTGTGCATGACTGCGTCAACATCACCGTCAAGCAGCACACAGTGACCAC
GACCACCAAGGGGGAGAACTTCACCGAGACGGACGTCAAGATGATAGAGCGCGTGGTGGAAACAGATGTGC
ATCACCCAGTACCAGAAAAGGTACGAGGCGTACGCCCAAAGAGGGGCCAGTGTGATCCTCTTCTCCTCCC
CTCCTGTGATCCTCCTCATCTCTTTCTCCTTTTCTCCTCATAGTGGGCTGAGGGTGGCCTTTCTGTGCGCA
TCATCTTCTTAATCTTTATCAGGTTGGGGGAGGGAATATCTACCTGCAGCCCTTTAGTGGTGGTGTCTCA
35 TTCTTGCTTCTCTCTTCGGCACCCATAGGCTAACATCCATGGCGCTTGTAGCACTGGAAAAGGAGAGTAG
ACCTGAGATGTGATGTATTTAAGCCCCATTTGATTGAATCCTTCATAGGCCAGTGCTAGTGCTGGACTGG
TAAGAGCGTAACAGCAAATAATCATTGGTTGATCTGGGCTCATTTTTTGTCTGGTGAACAGATTGAGGC
TAAAACAATTCTCAAAACACACTTCAAGTACCTTTACCTAAATACCTCCAGCTCCTTCTCCAGCTAGAGC
TCAGTACACAAATGCCCCGCCATAGTAGTGATTTTGTAGCAACTTTCCCATTTAAGAAAACCTGACTACA

TTTTCCTGTTCAAATAGCATTTCTACTGAGTTGGGGAGGAGGCCACATAATACTCATTCAAAAAAATGAA
 ACTGGAAATCCTTAGCTCCTGGGCCCAGGGTCAGCCCAGTGGAAAGCATGTGTCCTGTGTCTGCAGAGAA
 CTAAGGATATTTTGCAATTTGCAGTACAGGTTACACAGCAGCTATTGCATCAAGAATGGATGTCTGTGCA
 AACTAGACTTCTGGGCAGAGGGCATTTTCACAGGCAATGAACATAACTCACATAATATGAAAGGCTCTG
 5 AAACCTTAAAAAATCCACCTGTGTGAGGAACCCCTCAGAGGCAGCCTTCTGTTATGGATGTTTAAAGCAC
 CTTTCATGGGGTAGTTCTTTCTTTAGTAATAACAACTATAGATAATTAAGGTAGTAGGACATGAAACAATC
 TTCTGGACATTGAGAACAAATCTCTTTTGTGTTTATCTGGGAACTGGAGTGATTTTGCCATTTCTTGG
 ATGAAGCCAGGAGATTTTAACATAGAGGAAGCTGCAGCTATAAAAACATCATATTTATTCATTTGATTGA
 GTCTTTTCATGGGCCAGTGCCGGTGTGGGCTAGCAAGCATATGATACCAAATATAGAGGGTTATGAAGAA
 10 AATGATTAGTGTACAAAAAGAGAAATGCTTACATTTCTTTATTGCTGTGTGCATAATTGTCAAAAATCAG
 AATTAGGTCCCTCAATTTCTATAATTGGCTTTTGAATCAAAGAATAGGAAGGCATTCCCCCCCCAAAAAGT
 TAAAGATGATAGAAATATGATCCATTCATATTAGGAAAAGAAATTCTGGTACTGTTATTTAAATAAGGCA
 AAATTATTCCCTGGATTGTTTGGTGTGTGCACCTAGCAGATATACATTACTCTTCTGCATTGTTATTGGC
 TTGCACTTTGTGGGTATCCTATGTAAAAAATATATGTATATATATATATTGCATATGACAACTTGGAA
 15 GATTTTGGTTAGAGCTGTTAACATCTGAATTATCAAATGCATTACTTGTTTTTGTAAAGGTACTAAATATT
 TAATAATACTTAAAGGAAACCCTTTGTGTGGTCCTTCGGCTTACAATGTGCCTGAATAGTTTTGTATA
 AGGATCCAGAGTGGCATTTGAAATTCGCATGTGCTTTATATTTTCTATATTGTAACTTTGCATGTACTT
 GTTTTATTGTATTAAAAAGTTTATAAATGTTTATTATCTGACTAAAATTAAAACAGGAGCTACAATGAG

20 SEQ ID NO: 2 500bp of upper homologous arm

CTTGGCACAGGGGCCCTAGGCCCATAGGTGCTGATAGCCCTCATTATAGCCCCATTAGC
 AGAGCTGCCAGGGTCCCTACAAGAAGGTGCCTGGTTACAAGAATTATTACTTTACTTATT
 TATGCACCATGTGGAAGTTTCCAGGCTAGAAGTCGAATCAGAGATGTAGCTGCTGGCCTA
 CGCCACAGCCATACCAGATCTGAGCTGCATCTGCGACCTCACCACAGCACACGGCAAGGC
 25 CAGGGATCGAACCCGCGTCCCTCATGGATACTAATCCATGGCTGGTTTCTGCTGAGTCATG
 ATGGGAACTCCCAGAATCACAAAAGCTCAAAGCTGTGGCAAACCCACCAGGTGTTTATTG
 GTTTTTCCAGTTTAGATACAATGTATCAAGCAGAGGTTATTTTTACCATAAGCATGTTGC
 TGGCATTCCACCTTTATCTTTTCTAAGAAACAGAGCCAGAAAATTATCTGAAGGTCAAAT
 TTGTCCTTAGAGAAGGAGAAAGAGTTGAGTTAAC

30

SEQ ID NO: 3 1000 bp lower homologous arm

CGGTTACATGCTGGGGAGTGCCATGAGCAGACCCCTGATACACTTTGGCAGTGACTATGA
 GGACCGTTACTATCGTGAAAACATGTACCGTTACCCCAACCAAGTGTACTACAGGCCAGT
 GGATCAGTACAGCAACCAGAACAGTTTTGTGCATGACTGCGTCAACATCACCGTCAAGCA
 35 GCACACAGTGACCACGACCACCAAGGGGGAGAACTTCACCGAGACGGACGTCAAGATGAT
 AGAGCGCGTGGTGGAAACAGATGTGCATCACCCAGTACCAGAAAGAGTACGAGGCGTACGC
 CCAAAGAGGGGCCAGTGTGATCCTCTTCTCCTCCCTCCTGTGATCCTCCTCATCTCTTT
 CCTCCTTTTCTCATAGTGGGCTGAGGGTGGCCTTTCTGTGCGCATCATCTTCTTAATCT

TTATCAGGTTGGGGGAGGGAATATCTACCTGCAGCCCTTTAGTGGTGGTGTCTCATTCTT
 GCTTCTCTCTTCGGCACCCATAGGCTAACATCCATGGCGCTTGTAGCACTGGAAAAGGAG
 AGTAGACCTGAGATGTGATGTATTTAAGCCCCATTTGATTGAATCCTTCATAGGCCAGTG
 CTAGTGCTGGACTGGTAAGAGCGTAACAGCAAATAATCATTGGTTGATCTGGGCTCATT
 5 TTTGTCTGGTGCAACAGATTGAGGCTAAAACAATTCTCAAAACACACTTCAAGTACCTTT
 ACCTAAATACCTCCAGCTCCTTCTCCAGCTAGAGCTCAGTACACAAATGCCCCGCCATAG
 TAGTGATTTTGTAGCAACTTTCCCATTTAAGAAAACCTGACTACATTTTCTGTTCAAAT
 AGCATTTCTACTGAGTTGGGGAGGAGGCCACATAATACTCATTCAAAAAAATGAACTGG
 AAATCCTTAGCTCCTGGGCCCAGGGTCAGCCAGTGGAAGCATGTGTCTGTGTCTGCA
 10 GAGAACTAAGGATATTTTGCAATTTGCAGTACAGGTTACACAGCAGCTATTGCATCAAG

SEQ ID NO: 4 Green fluorescent protein encoding sequence

ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGTGGTGCCCATCCTGGTCGAGCTGGAC
 GGCGACGTGAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTAC
 15 GGCAAGCTGACCCTGAAGTTCATCTGCACCACCGCAAGCTGCCCCGTGCCCTGGCCCACC
 CTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAG
 CAGCACGACTTCTTCAAGTCCGCCATGCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
 TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTG
 GTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCAC
 20 AAGCTGGAGTACAACACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAAC
 GGCATCAAGGTGAACCTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCC
 GACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCCACAACCAC
 TACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTC
 CTGCTGGAGTTTCGTGACCGCCGCCGGGATCACTCACGGCATGGACGAGCTGTACAAGTAA
 25

SEQ ID NO: 5, 6, 7, 8 primers used to obtain the upper and lower arms

PRNP upper arm MluI for: CTAGACGCGTCTTGGCACAGGGGCCCTAG

PRNP upper arm BsiW1 rev: GACTACGTACGCCTACCACTGCCCCAGCTG

PRNP lower arm XhoI for: GACTCTCGAGCGGTTACATGCTGGGGAGT

30 PRNP lower arm AscI rev: GTCAGGCGCGCCTTGATGCAATAGCTGCTGT

Targeting vector is generated by digesting with AscI (introduced by the primer) and HpaI enzyme on the endogenous sequence.

SEQ ID NO: 9 and 10 primers inside and outside vector to confirm GFP

35 Inside the GFP expression vector: CCAGCTGGGGCTCGACTAGA

Outside the homology arm: CCATTTTGAGCAGCCTCATTG

SEQ ID NO: 11 LoxP nucleotide sequence

ATAACTTCGTATAATGTATGCTATACGAACGGTA

5 SEQ ID NO: 12: single stranded oligo used to target ZBED

GGTGGCAGAA GGAGTGGATA AAGAGGCAAA ATTGCCTGCC AAAAAGAAAA
GAAAGAAGGGTTTGC (EcoR1 site follows in italics) *GAATTC* (LoxP site follows in
lower case) taccgttcgtatagcatacattatacgaagttat AGGGGAAAA GGCGACGAAA
GAAACTGATC CTTGCAAAAA AGTTTAGTAA GGATTTGGGA TCTGGGAGGC
10 CTGTTGCAAG

SEQ ID NO: 13 is the *ZBED6* sequences shown in Figure 6 with the EcoRI and LoxP
insert Blastocyst 1 and 5

AGAAGGGTTTGCGAATTCTACCGTTCGTATAGCATACTATTATACGAAGTTATAGGGGAAAAGGCGAC

15

SEQ ID NO: 14 and 15 flanking sequence for ss oligo

Upper: GGTGGCAGAA GGAGTGGATA AAGAGGCAAA

ATTGCCTGCCAAAAAGAAAA GAAAGAAGGGTTTGCGAATTC

20 Lower: AGGGGAAAA GGCGACGAAA GAAACTGATC CTTGCAAAAA
AGTTTAGTAA GGATTTGGGA TCTGGGAGGC CTGTTGCAAG

SEQ ID NO:16

25 ZBED insert from Blastocyst 3 and 4 from Figure 6

AGAAGGGTTTGCGAATTCTACCGTTCGTATAGCATACTATTATACGAAGTTAAGGGGAAAAGGCGAC

SEQ ID NO:17

ZBED insert blastocyst 2 from Figure 6

30 AGAAGGGTTTGCGAATTCTACCGTTCGTATAGCATACTATTATACGAAGTTAAGGGGAAAAGGCGGC

What is claimed is:

1. A method of targeted gene editing of an animal genome, the method comprising:
 - a) producing a zygote comprising said genome of said animal by fertilizing animal oocyte and animal spermatozoa;
 - 5 b) injecting into said zygote a composition one or more vectors comprising:
 - i. a nuclease;
 - ii. at least one guide nucleic acid molecule that targets said nuclease to a target gene of said genome at a target locus;
 - 10 iii. a single stranded oligonucleotide or double stranded nucleic acid molecule comprising a heterologous nucleic acid molecule of interest (NOI);
 - iv. a sequence homologous to a first flanking sequence upstream of said target locus and a second sequence comprising a second flanking sequence downstream of said target locus;
 - 15 c) said composition injected into said cell before said zygotic cell forms a single nucleus;
 - d) said nuclease introducing a double stranded break at said target locus of said target gene of said animal genome; and
 - 20 e) said NOI recombined into said target locus of said target gene of said animal genome.
2. The method of claim 1, where the composition is injected into the cytoplasm of said zygotic cell.
- 25 3. The method of claim 1, wherein said composition is injected up to 24 hours after fertilization.
4. The method of claim 1, wherein said composition is injected at least three hours to 16 hours after fertilization
- 30 5. The method of claim 1, wherein said composition is injected 12 to 16 hours after fertilization.

6. The method of claim 1, wherein said composition is injected 16 hours after fertilization.
- 5 7. The method of claim 1, where expression of said target gene is modified.
8. The method of claim 1, wherein said NOI expresses a polypeptide.
9. The method of claim 1, wherein at least one phenotype of said animal is modified
10 after said NOI is recombined into said animal genome.
10. The method of claim 1, wherein said animal is a ruminant animal.
11. The method of claim 1, wherein said animal is swine or bovine.
- 15 12. The method of claim 1, wherein said animal is swine.
13. The method of claim 1, wherein said composition comprises a single stranded oligonucleotide comprising said NOI.
- 20 14. The method of claim 13, wherein said flanking sequences comprise 50 or fewer base pairs.
15. The method of claim 1, wherein said composition comprises a double stranded
25 nucleic acid molecule comprising said NOI.
16. The method of claim 15, wherein said flanking sequences comprise 1000 or fewer base pairs.
- 30 17. The method of claim 1, wherein said flanking sequences comprise less than 5000 base pairs.

18. The method of claim 1, wherein said composition comprises a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) – CRISPR associated (Cas) system comprising one or more expression vectors comprising a guide RNA that hybridizes with said target gene and a Cas9 protein.

5

19. A method of targeted gene editing of an animal genome of an animal having pronuclei that cannot be visually observed by the unaided human eye, the method comprising:

- a) producing a zygote comprising said genome of said animal by fertilizing
10 animal oocyte and animal spermatozoa;
- b) injecting into said zygote a composition comprising one or more vectors comprising:
 - i. at least one nucleotide sequence encoding a Clustered Regularly
Interspaced Short Palindromic Repeat (CRISPR) – CRISPR
15 associated (Cas) system comprising one or more expression vectors comprising:
 - (a) a guide RNA that hybridizes with a target gene of said
animal;
 - (b) a nucleotide sequence encoding a Cas9 protein;
 - ii. a single stranded oligonucleotide or double stranded nucleic acid
20 molecule comprising a heterologous nucleic acid molecule of interest (NOI);
 - iii. a sequence homologous to a first flanking sequence upstream of said
target locus and a second sequence comprising a second flanking
25 sequence downstream of said target locus;
- c) said composition injected into said cell before said zygotic cell forms a
single nucleus;
- d) said nuclease introducing a double stranded break at said target locus of said
target gene of said animal genome; and
- 30 e) said NOI recombined into said target locus of said target gene of said
animal genome.

20. A method of predicting impact of integration of a nucleic acid molecule into human genome, the method comprising:

- a) producing a zygote comprising said genome of a porcine animal by fertilizing porcine animal oocyte and porcine animal spermatozoa;
- 5 b) injecting into said zygote a composition comprising one or more vectors comprising:
 - i. a nuclease;
 - ii. at least one guide nucleic acid molecule that targets said nuclease to a target gene of said genome at a target locus;
 - 10 iii. a single stranded oligonucleotide or double stranded nucleic acid molecule comprising a heterologous nucleic acid molecule of interest (NOI);
 - iv. a sequence homologous to a first flanking sequence upstream of said target locus and a second sequence comprising a second flanking

sequence downstream of said target locus;
 - 15 c) said composition injected into said zygote before said zygote forms a single nucleus;
 - d) said nuclease introducing a double stranded break at said target locus of said target gene of said porcine animal genome;
 - 20 e) said NOI recombined into said target locus of said target gene of said porcine animal genome;
 - f) producing a porcine animal from said zygote;
 - g) determining any genotypic or phenotypic changes in said porcine animal and predicting impact of integration of said NOI into a human genome as a

25 result of said changes in said porcine animal.

21. An edited ZBED nucleic acid sequence having an insertion sequence.

22. The edited ZBED sequence of claim 21 comprising SEQ ID NO 13, 16 or 17.


23. A pig with an edited ZBED sequence having increased growth performance when compared to a pig with a wild type ZBED sequence.

24. The pig of claim 23 wherein said ZBED sequence is SEQ ID NO:13, 16, or 17.

1/7



Mouse zygote



Pig zygote

FIG. 1

2/7




FIG. 2A




FIG. 2B

3/7




FIG. 3A




FIG. 3B

4/7



FIG. 4

5/7




FIG. 5A




FIG. 5B

6/7

Crispr-Cas9&sgRNA+Loxp oligo (Zbed6)**Blastocyst 1**

Zbed6	AGAAGGGTTTGCGAATTA	-----	AGGGGAAAAGGCGAC
1	AGAAGGGTTTGCGAATTC	TACCGTTCGTATAGCATACATTATACGAAGTTAT	AGGGGAAAAGGCGAC
2	AGAAGGGTTTGCGAATTC	TACCGTTCGTATAGCATACATTATACGAAGTTAT	AGGGGAAAAGGCGAC
3	AGAAGGGTTTGCGAATTC	TACCGTTCGTATAGCATACATTATACGAAGTTAT	AGGGGAAAAGGCGAC

Blastocyst 2

Zbed6	AGAAGGGTTTGCGAATTA	-----	AGGGGAAAAGGCGAC
1	AGAAGGGTTTGCGAATTC	TACCGTTCGTATGCATACATTATACGAAGTTA	AGGGGAAAAGGCGGC
2	AGAAGGGTTTGCGAATTC	TACCGTTCGTATGCATACATTATACGAAGTTA	AGGGGAAAAGGCGGC

Blastocyst 3

Zbed6	AGAAGGGTTTGCGAATTA	-----	AAGGGGAAAAGGCGAC
1	AGAAGGGTTTGCGAATTC	TACCGTTCGTATGCATACATTATACGAAGTTA	AAGGGGAAAAGGCGAC
2	AGAAGGGTTTGCGAATTC	TACCGTTCGTATGCATACATTATACGAAGTTA	AAGGGGAAAAGGCGAC
3	AGAAGGGTTTGCGAATTC	TACCGTTCGTATGCATACATTATACGAAGTTA	AAGGGGAAAAGGCGAC



Blastocyst 4

Zbed6	AGAAGGGTTTGCGAATTA	-----	AGGGGAAAAGGCGAC
1	AGAAGGGTTTGCGAATTC	TACCGTTCGTATGCATACATTATACGAAGTTA	AAGGGGAAAAGGCGAC
2	AGAAGGGTTTGCGAATTC	TACCGTTCGTATGCATACATTATACGAAGTTA	AAGGGGAAAAGGCGAC

Blastocyst 5


Zbed6	AGAAGGGTTTGCGAATTA	-----	AGGGGAAAAGGCGAC
1	AGAAGGGTTTGCGAATTC	TACCGTTCGTATAGCATACATTATACGAAGTTAT	AGGGGAAAAGGCGAC
2	AGAAGGGTTTGCGAATTC	TACCGTTCGTATAGCATACATTATACGAAGTTAT	AGGGGAAAAGGCGAC

FIG. 6



Zbed6 with loxp
(70% targeting)

FIG. 7B



PRNP with loxp
(100% targeting)

FIG. 7C

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 15/22660

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - C12N 15/00; C12N 15/85 (2015.01)

CPC - C12N 15/8509; A01K 2217/05

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

CPC: C12N 15/8509; A01K 2217/05

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

CPC: C12N 15/8509; A01K 2217/05 (text search)

435/375, 455; 800/25, 17, 18 (text search)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Electronic data bases: PatBase; Google Scholar; Google Patents

Search terms: Genome editing, animal, zygote, microinjection, CRISPR/Cas9, insertion, flanking homology, recombination, swine, bovine, mouse

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ----- Y	YANG et al. One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell 12 September 2013 Vol 154 No 6 Pages 1370-1379. Especially pg 1371 col 1 para 2 and 3, pg 1372 fig 1A,D, pg 1373 col para 1, pg 1375 fig 2A, pg 1378 col 1 para 2.	1,2, 7-9, 13-19 ----- 3-6, 10-12, 20
Y	US 2012/0276537 A1 (KUHN et al.) 01 November 2012 (01.11.2012). Especially para [0042], [0046], [0049].	3-6
Y	HAI et al. One-step generation of knockout pigs by zygote injection of CRISPR/Cas system. Cell Research ePub 31 January 2014 Vol 24 No 3 Pages 372-375. Especially pg 375 col 1 para 2.	10-12, 20

☐ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

24 July 2015 (24.07.2015)

Date of mailing of the international search report

13 AUG 2015

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 15/22660

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:

a. ☒ forming part of the international application as filed:

☒ in the form of an Annex C/ST.25 text file.

☐ on paper or in the form of an image file.

b. ☐ furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.

c. ☐ furnished subsequent to the international filing date for the purposes of international search only:

☐ in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).

☐ on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).

2. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments:

GenCore ver 6.4.1 SEQ ID NOs: 13, 16, 17

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 15/22660

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
-----go to Extra Sheet for continuation-----

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-20

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 15/22660

continuation of Box III (Lack of Unity of Invention)

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I: Claims 1-20 drawn to a method of targeted genome editing of an animal.

Group II: Claims 21-24, drawn to a composition comprising an edited ZBED sequence.

The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Special Technical Features:

Group I has the special technical feature of particular method steps including producing a zygote and injecting a particular composition into said zygote under specific conditions, not required by Group II.

Group II has the special technical feature of a composition including an edited ZBED sequence, not required by Group I.

Common Technical Feature:

Groups I and II share the common technical feature of targeted genome editing of an animal.

However, said common technical feature does not represent a contribution over the prior art, and is anticipated by the publication titled "One-step generation of knockout pigs by zygote injection of CRISPR/Cas system" by HAI et al. (hereinafter "Hai") [ePub 31 January 2014 in Cell Research Vol 24 No 3 Pages 372-375].

Hai teaches targeted genome editing of an animal (pg 375 col 1 para 2; "we have shown that zygote injection of the CRISPR/Cas system can efficiently generate genome-modified pigs in one step, resulting in rapid establishment of large animal model for important human diseases"; pg 372 col 1 para 3; "To demonstrate the application of genome engineering in disease modeling and agriculture, we chose to target vWF gene, whose deficiency in human causes severe von Willebrand disease (vWD)").

As the common technical feature was known in the art at the time of the invention, this cannot be considered a common special technical feature that would otherwise unify the groups. The inventions lack unity with one another.

Therefore, Groups I and II lack unity of invention under PCT Rule 13 because they do not share a same or corresponding special technical feature.